文献速递银屑病与炎症性皮肤病

古塞奇尤单抗治疗中重度银屑病长达5年的安全性:七项临床试验汇总分析(超过8600患者年暴露)

Safety of guselkumab treatment for up to 5 years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposure.
PubMed 文献 · Br J Dermatol · 2023-01-01

汇总七项II/III期临床试验,评估古塞奇尤单抗治疗中重度斑块状银屑病的安全性。安慰剂对照期(0-16周)古塞奇尤单抗组与安慰剂组不良事件发生率相似;长达5年随访中,古塞奇尤单抗治疗患者(2891例,8662患者年)的安全性事件发生率低于或与安慰剂对照期相当,未发现与古塞奇尤单抗相关的克罗恩病、溃疡性结肠炎、机会性感染或活动性结核。

要点

  • 安慰剂对照期古塞奇尤单抗组不良事件346/100患者年,安慰剂组341/100患者年。
  • 长达5年随访中古塞奇尤单抗治疗患者不良事件发生率169/100患者年,低于安慰剂对照期。
  • 未发现与古塞奇尤单抗相关的克罗恩病、溃疡性结肠炎、机会性感染或活动性结核病例。

核心结论

  • 在这项纳入2891例古塞奇尤单抗治疗患者、随访长达5年(8662患者年)的综合分析中,古塞奇尤单抗显示出良好的安全性,与既往报告一致。
  • 古塞奇尤单抗治疗患者的安全性事件发生率与安慰剂观察到的相似,并在长期治疗中保持一致。

研究设计与样本

  • 汇总七项II/III期研究(X-PLORE、VOYAGE 1、VOYAGE 2、NAVIGATE、ORION、ECLIPSE、日本注册研究)的数据。
  • 除NAVIGATE和ECLIPSE(仅活性对照)外,所有研究均包括16周安慰剂对照期;X-PLORE、VOYAGE 1和VOYAGE 2包括安慰剂和活性对照。
  • 大多数研究中,古塞奇尤单抗治疗患者在第0周、第4周接受100 mg皮下注射,此后每8周一次。
  • 安全性数据汇总用于安慰剂对照期(第0-16周)和至报告期末(长达5年),关键安全性事件发生率经事后整合,按随访时间调整,以每100患者年(PY)报告。

主要发现

  • 安慰剂对照期,544例患者接受安慰剂(165 PY),1220例接受古塞奇尤单抗(378 PY)。
  • 至报告期末,2891例古塞奇尤单抗治疗患者贡献8662 PY随访。
  • 安慰剂对照期,古塞奇尤单抗组和安慰剂组不良事件发生率分别为346/100 PY和341/100 PY,感染分别为95.9/100 PY和83.6/100 PY。
  • 严重不良事件(6.3/100 PY vs. 6.7/100 PY)、导致停药的不良事件(5.0/100 PY vs. 9.7/100 PY)、严重感染(1.1/100 PY vs. 1.2/100 PY)、恶性肿瘤(0.5患者/100 PY vs. 0.0患者/100 PY)和主要不良心血管事件(MACE;0.3/100 PY vs. 0.0/100 PY)在古塞奇尤单抗组和安慰剂组均较低且相当。
  • 至报告期末,古塞奇尤单抗治疗患者的安全性事件发生率低于或与安慰剂对照期相当:不良事件169/100 PY;感染65.9/100 PY;严重不良事件5.3/100 PY;导致停药的不良事件1.6/100 PY;严重感染0.9/100 PY;恶性肿瘤0.7/100 PY;MACE 0.3/100 PY。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Guselkumab has demonstrated favourable safety and efficacy across individual clinical studies in adults with moderate-to-severe plaque psoriasis. OBJECTIVES: To evaluate the safety of guselkumab in patients with psoriasis using pooled data from seven phase II/III studies (X-PLORE, VOYAGE 1, VOYAGE 2, NAVIGATE, ORION, ECLIPSE, Japan registration). METHODS: All studies, except NAVIGATE and ECLIPSE (active comparator-controlled only), included a 16-week placebo-controlled period; X-PLORE, VOYAGE 1 and VOYAGE 2 included both placebo and active controls. In most studies, guselkumab-treated patients received 100-mg subcutaneous injections at week 0, week 4, and then every 8 weeks thereafter. Safety data were summarized for the placebo-controlled period (weeks 0-16) and through the end of the reporting period (up to 5 years). Incidence rates of key safety events were integrated post hoc, adjusted for the duration of follow-up and reported per 100 patient-years (PY). RESULTS: During the placebo-controlled period, 544 patients received placebo (165 PY) and 1220 received guselkumab (378 PY). Through the end of the reporting period, 2891 guselkumab-treated patients contributed 8662 PY of follow-up. During the placebo-controlled period, in the guselkumab and placebo groups, respectively, rates of adverse events (AEs) were 346/100 PY and 341/100 PY, and infections were 95.9/100 PY and 83.6/100 PY. Rates of serious AEs (6.3/100 PY vs. 6.7/100 PY), AEs leading to discontinuation (5.0/100 PY vs. 9.7/100 PY), serious infections (1.1/100 PY vs. 1.2/100 PY), malignancy (0.5 patients/100 PY vs. 0.0 patients/100 PY) and major adverse cardiovascular events (MACE; 0.3/100 PY vs. 0.0/100 PY) were low and comparable between guselkumab and placebo. Through the end of the reporting period, safety event rates were lower than or comparable to the placebo-controlled period in guselkumab-treated patients: AEs, 169/100 PY; infections, 65.9/100 PY; serious AEs, 5.3/100 PY; AEs leading to discontinuation, 1.6/100 PY; serious infections, 0.9/100 PY; malignancy, 0.7/100 PY; and MACE, 0.3/100 PY. There were no cases of Crohn disease, ulcerative colitis, opportunistic infection or active tuberculosis related to guselkumab. CONCLUSIONS: In this comprehensive analysis of 2891 guselkumab-treated patients with psoriasis followed for up to 5 years (8662 PY), guselkumab demonstrated favourable safety, consistent with previous reports. Safety event rates in guselkumab-treated patients were similar to those observed with placebo and were consistent throughout long-term treatment.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Lebwohl MG, Merola JF, Rowland K, et al. Safety of guselkumab treatment for up to 5 years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposure. Br J Dermatol. 2023. PMID: 37022762. doi:10.1093/bjd/ljad115

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。